|
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One effervescent tablet contains:
1500 mg calcium carbonate (equivalent to 600 mg or 15 mmol
elemental calcium)
400 I.U. or 10 micrograms colecalciferol (vitamin D3) as
colecalciferol concentrate ‘powder form’
This product also contains sucrose (part of the vitamin D3
concentrate: approximately 1.5 micrograms per tablet) and soya oil (also part
of the vitamin D3 concentrate: approximately 0.3 milligrams per tablet).
For a full list of excipients see Section 6.1
|
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One effervescent tablet contains:
1500 mg calcium carbonate (equivalent to 600 mg or 15 mmol
elemental calcium)
400 I.U. or 10 micrograms colecalciferol (vitamin D3) as
colecalciferol concentrate ‘powder form.’
This product also contains sucrose (part of the vitamin D3
concentrate: approximately 1.7
milligrams per tablet) and soya oil (also part of the vitamin D3 concentrate:
approximately 0.3 milligrams per tablet).
For a full list of excipients see Section 6.1.
|
|
4.4
Special warnings and precautions for use
Patients with mild to moderate renal failure or mild hypercalciuria
should be supervised carefully including periodic checks of plasma calcium
levels and urinary calcium excretion.
In patients with a history of renal stones urinary calcium
excretion should be measured to exclude hypercalciuria.
With long-term treatment it is advisable to monitor serum
and urinary calcium levels and kidney function, and reduce or stop treatment
temporarily if urinary calcium exceeds 7.5mmol/24 hours (300mg/24 hours).
Caution is required in patients receiving treatment for cardiovascular
disease (see Section 4.5 – thiazide diuretics and cardiac glycosides
including digitalis).
Adcal-D3 Dissolve should also be used with caution in
other patients with increased risk of hypercalcaemia e.g. patients with
sarcoidosis or those suffering from malignancies.
Patients with rare hereditary problems of fructose
intolerance, glucose-galactose malabsorption or sucrase-isomaltase
insuffiency should not take this medicine.
Allowances should be made for calcium and vitamin D
supplements from other sources.
Information for diabetics:
Patients who have diabetes mellitus or require a low-sugar
diet should take account of the sucrose content of this medicinal product.
One effervescent tablet contains 1.672mg of sucrose.
|
4.4
Special warnings and precautions for use
Patients with mild to moderate renal failure or mild
hypercalciuria should be supervised carefully including periodic checks of
plasma calcium levels and urinary calcium excretion.
In patients with a history of renal stones urinary calcium
excretion should be measured to exclude hypercalciuria.
With long-term treatment it is advisable to monitor serum
and urinary calcium levels and kidney function, and reduce or stop treatment
temporarily if urinary calcium exceeds 7.5mmol/24 hours (300mg/24 hours).
Caution is required in patients receiving treatment for
cardiovascular disease (see Section 4.5 – thiazide diuretics and cardiac
glycosides including digitalis).
Adcal-D3 Dissolve should also be used with caution in
other patients with increased risk of hypercalcaemia e.g. patients with
sarcoidosis or those suffering from malignancies.
Patients with rare hereditary problems of fructose
intolerance, glucose-galactose malabsorption or sucrase-isomaltase insuffiency
should not take this medicine.
Each
tablet contains a small amount of sugar (about 1.7 mg per tablet) and may be
harmful to teeth if used for a prolonged period.
Allowances should be made for calcium and vitamin D
supplements from other sources.
Information for diabetics:
Patients who have diabetes mellitus or require a low-sugar
diet should take account of the sucrose content of this medicinal product.
One effervescent tablet contains 1.672mg of sucrose.
|
